Euro Surveill. Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020

[tetano]

Euro Surveill. 2020 Mar;25(11). doi: 10.2807/1560-7917.ES.2020.25.11.2000266.
Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020.


Haveri A¹, Smura T², Kuivanen S², ?sterlund P¹, Hepojoki J^3,2, Ikonen N¹, Pitk?paasi M¹, Blomqvist S¹, R?nkk? E¹, Kantele A⁴, Strandin T², Kallio-Kokko H⁵, Mannonen L⁵, Lappalainen M⁵, Broas M⁶, Jiang M^7,1, Siira L¹, Salminen M¹, Puumalainen T¹, Sane J¹, Melin M¹, Vapalahti O^5,2, Savolainen-Kopra C¹.

Author information




Abstract

The first case of coronavirus disease (COVID-19) in Finland was confirmed on 29 January 2020. No secondary cases were detected. We describe the clinical picture and laboratory findings 3-23 days since the first symptoms. The SARS-CoV-2/Finland/1/2020 virus strain was isolated, the genome showing a single nucleotide substitution to the reference strain from Wuhan. Neutralising antibody response appeared within 9 days along with specific IgM and IgG response, targeting particularly nucleocapsid and spike proteins.



KEYWORDS:

COVID-19; SARS-CoV-2; antibodies; coronavirus; humoral immunity; immunofluorescence assay; microneutralisation test; western blotting; whole-genome sequencing


PMID:32209163DOI:10.2807/1560-7917.ES.2020.25.11.2000266